Shares of Diffusion Pharmaceuticals (NASDAQ: DFFN) surged as much as 23% this morning after the company announced that the U.S. Patent and Trademark Office (USPTO) has issued a key patent for the company’s lead drug candidate, trans sodium crocetinate (TSC). Diffusion’s existing patents currently include the use of TSC in oncology, stroke and neurodegenerative disease indications. The new patent increases coverage of the therapeutic use of TSC and other related compounds to five hypoxia-related conditions including congestive heart failure, chronic renal failure, acute lung injury, chronic obstructive pulmonary disease, and respiratory distress syndrome. “Receiving the patent from the USPTO validates the potential of TSC to serve as a primary therapeutic agent in many conditions involving hypoxia and expands our patent estate. We look forward to advancing the clinical development of our lead compound,” chairman and CEO David Kalergis stated in the news release.
To view the full press release, visit: http://nnw.fm/0bRv3
About Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. is a clinical stage biotechnology company focused on treating the many life threatening diseases that involve hypoxia. The current primary focus is extending the life expectancy of cancer patients by improving the effectiveness of current standard of care treatments including radiation therapy and chemotherapy. Diffusion is developing trans sodium crocetinate (TSC), for use in the many cancer types in which tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of current treatments. TSC targets the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of treatments such as radiation therapy and chemotherapy, without the apparent addition of any serious side effects. For more information visit www.diffusionpharma.com.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
